Dyne Therapeutics News and Activities
Presence
Dyne Therapeutics develops genetic medicines for serious muscle diseases. Its products and services include oligonucleotide therapies and research programs for patients, healthcare providers, and partners in rare disease care.
Dyne Therapeutics products and services overview:
- Genetic medicines
- Oligonucleotide therapies
- Muscle disease treatments
- Rare disease research
- Clinical development
Revenue: ~$23 million
Employees: 280
Headquarters: Waltham, United States (USA)
Dyne Therapeutics is one of the...
Dyne Therapeutics is a company listed under the stock ticker DYN (US).
Executives
View the org chart displaying its 43 main executives
Most searched biographies at Dyne Therapeutics
- John Cox, President, Chief Executive Officer and Director
- Dirk Kersten, Director
- Ed Hurwitz, Director
Popular executive movements at Dyne Therapeutics
- Barry Greene has joined the company as Director (posted on June 23 2026).
- Vikram Karnani has joined the company as Director (posted on December 23 2025).
Create your alert
to follow the executive moves at Dyne Therapeutics.
Biotechnology
Dyne Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
- MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
- Chemomab and Scipher Medicine have announced they will merge (posted on July 13 2026)..
Popular contacts in Biotechnology
News
Press releases by Dyne Therapeutics
- Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights | Dyne Therapeutics
- Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 | Dyne Therapeutics
- Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy | Dyne Therapeutics
- Dyne Therapeutics to Present at Jefferies Global Healthcare Conference | Dyne Therapeutics
- Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown | Dyne Therapeutics
- Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights | Dyne Therapeutics
- Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights | Dyne Therapeutics
- Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors | Dyne Therapeutics
- Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021 | Dyne Therapeutics
- Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference | Dyne Therapeutics
- View more press releases Close
Social media about Dyne Therapeutics
- Dyne Therapeutics on Wikipedia, Google News & Yahoo Finance
- Dyne Therapeutics on LinkedIn, X (Twitter) & YouTube
